The influence of Fe(III) incorporation on anti-cancer potential of a Wells- Dawson nanocluster

2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023 (419-422)

АУТОР(И) / AUTHOR(S): Mirjana B. Čolović, Lela B. Korićanac, Jelena J. Žakula,  Nada Savić, Tatjana Parac-Vogt, Danijela Z. Krstić

Е-АДРЕСА / E-MAIL: colovicm@vin.bg.ac.rs

Download Full Pdf  

DOI: 10.46793/ICCBI23.419C

САЖЕТАК / ABSTRACT:

The objective of this study was to evaluate in vitro the antitumor properties of Fe(III)-substituted monolacunary Wells-Dawson polyoxotungstate, K7[FeIII(α2-P2W17O61)(H2O)] (FeWD) using cervical carcinoma HeLa cells as a model system. HeLa cells were exposed in vitro to FeWD within the concentration range from 0.001 to 1 mM, for 24, 48, and 72 hours. The studied Fe(III)- substituted polyoxotungstate affected HeLa cell viability in a concentration- and time-dependent manner. The obtained IC50 values (μM), as an indicator of the cytotoxic potential of FeWD, were: 16.64 ± 0.49, 10.75 ± 0.97, and 9.64 ± 0.19 for 24-, 48-, and 72-hour treatment, respectively. FeWD exhibited a stronger antitumor potential against HeLa cells than the structurally similar monolacunary Wells-Dawson polyoxotungstate, K10P2W17O61.20H2O (lacunary WD). Lacunary WD achieved IC50 at 24,11 μM after 24-hour exposure, which is about 44% higher concentration compared to the corresponding IC50 obtained for FeWD. This indicates that incorporating Fe(III) might be a new strategy for improving the antitumor efficacy of polyoxometalates as promising candidates for next-generation chemotherapeutics.

КЉУЧНЕ РЕЧИ / KEYWORDS:

Fe(III)-substituted polyoxotungstate, HeLa cells, in vitro cytotoxicity, metallodrugs, Wells-Dawson

ЛИТЕРАТУРА / REFERENCES:

  • M.B. Čolović, M. Lacković, J. Lalatović, A.S. Mougharbel, U. Kortz, D.Z. Krstić, Polyoxometalates in biomedicine: update and overview, Current Medicinal Chemistry, 27 (2020) 362-379.

  • A.M. Isakovic, M.B. Čolović, T. Ma, X. Ma, M. Jeremic, M. Gerić, G. Gajski, S. Misirlic‐Dencic, U. Kortz, D. Krstić, Selected polyoxopalladates as promising and selective antitumor drug candidates, Journal of Biological Inorganic Chemistry, 26 (2021) 957–971.

  • D.K. Lyon, W.K Miller, T. Novet, P.J. Domaille, E. Evitt, D.C. Johnson, R.G. Finke, Highly oxidation resistant inorganic-porphyrin analog polyoxometalate oxidation catalysts. 1. The synthesis and characterization of aqueous-soluble potassium salts of α2-P2W17O61(Mn+.OH2)(n-10) and organic solvent soluble tetra-n-butylammonium salts A2-P2W 17061(Mn+.Br)(n-l l) (M=Mn3+, Fe3+, Co2+,Ni2+, Cu2+). Journal of the American Chemical Society, 113 (1991) 7209–7221.

  • P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, Journal of the National Cancer Institute, 82 (1990) 1107-1112.